| Jeffrey Ira Gerry, MDPHD | |
|
9155 Sw Barnes Rd, Ste 204, Portland, OR 97225-6625 | |
| (503) 297-7463 | |
| (503) 297-8835 |
| Full Name | Jeffrey Ira Gerry |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 34 Years |
| Location | 9155 Sw Barnes Rd, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396727400 | NPI | - | NPPES |
| 010350 | Medicaid | OR | |
| 018132001 | Other | OR | BLUE CROSS |
| 1057847 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | MD16613 (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fanno Creek Clinic Llc | 0042100521 | 24 |
News Archive
It is easy to tell a medical research story that has a simple and dramatic moment. But disease is often much more complex, and the work to understand it can be painstaking. A vivid example of that is seen in the University of Alabama at Birmingham Medical Genomics Laboratory, headed by Ludwine Messiaen, Ph.D., professor of genetics. This lab offers clinical genetic testing for a broad array of common and rare genetic disorders.
Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.
› Verified 4 days ago
| Entity Name | Fanno Creek Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609876705 PECOS PAC ID: 0042100521 Enrollment ID: O20040318000244 |
News Archive
It is easy to tell a medical research story that has a simple and dramatic moment. But disease is often much more complex, and the work to understand it can be painstaking. A vivid example of that is seen in the University of Alabama at Birmingham Medical Genomics Laboratory, headed by Ludwine Messiaen, Ph.D., professor of genetics. This lab offers clinical genetic testing for a broad array of common and rare genetic disorders.
Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Ira Gerry, MDPHD Po Box 821350, Vancouver, WA 98682-0030 Ph: (503) 283-5220 | Jeffrey Ira Gerry, MDPHD 9155 Sw Barnes Rd, Ste 204, Portland, OR 97225-6625 Ph: (503) 297-7463 |
News Archive
It is easy to tell a medical research story that has a simple and dramatic moment. But disease is often much more complex, and the work to understand it can be painstaking. A vivid example of that is seen in the University of Alabama at Birmingham Medical Genomics Laboratory, headed by Ludwine Messiaen, Ph.D., professor of genetics. This lab offers clinical genetic testing for a broad array of common and rare genetic disorders.
Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.
› Verified 4 days ago
Danielle Laure Erb, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1815 Sw Marlow Ave, Suite 110, Portland, OR 97225 Phone: 503-296-0918 Fax: 503-296-6158 | |
Dr. Duncan Soule, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2617 Nw Thurman St, Portland, OR 97210 Phone: 503-224-9010 Fax: 503-224-5551 | |
Dr. Stephanie K Liu, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10940 Sw Barnes Rd # 375, Portland, OR 97225 Phone: 646-591-7011 | |
Thomas Lorish, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 9155 Sw Barnes Rd, #440, Portland, OR 97225 Phone: 503-216-7145 Fax: 503-216-4071 | |
Dr. Lynette Santos Malik, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3600 N Interstate Ave, Department Of Physical Medicine, Portland, OR 97227 Phone: 503-331-3070 Fax: 503-331-3089 | |
Dr. Gary Allen Ward, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1040 Nw 22nd Ave, Suite 320, Portland, OR 97210 Phone: 503-413-6294 Fax: 503-413-7780 | |
Steven James Janselewitz, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2801 N Gantenbein Ave, Portland, OR 97227 Phone: 503-413-4505 |